Unknown

Dataset Information

0

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.


ABSTRACT:

Background

Protein levels of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) determined by enzyme-linked immunosorbent assay from fresh-frozen tumor tissue have been evaluated as prognostic factors in prospectively randomized trials in breast cancer. However, the role of uPA and PAI-1 in the context of breast cancer subtypes and for mRNA expression of these factors is less clear.

Methods

We evaluated uPA and PAI-1 mRNA expression using the Affymetrix HG-U 133A array within molecular subgroups of breast cancer in cohorts of patients with systemic treatment (cohort A, n=362) and without systemic treatment (cohort B, n=200). We validated mRNA expression in a cohort of HER2-positive breast cancer patients (cohort C, n=290). Luminal, triple-negative, and HER2-positive subcohorts were defined by ESR1 and ERBB2 mRNA expression using predefined cutoffs.

Results

In the entire cohort A, elevated PAI-1 but not uPA mRNA expression was associated with shorter disease-free survival (P=0.007 for PAI and 0.069 for uPA). Regarding different molecular subgroups, 67% (n=244) of tumors were luminal, 14% (n=49) were HER2-positive, and 19% (n=69) were triple-negative. Elevated PAI-1 mRNA expression was associated with shorter disease-free survival only in the HER2-positive subgroup (P=0.031). The same disease-free survival results were found for uPA in HER2-positive patients (P=0.011). In contrast, no association between either marker and survival was observed in the luminal or triple-negative subgroups. In the HER2-positive validation cohort C, elevated uPA and PAI-1 mRNA expression also showed strong associations with shorter disease-free survival (P=0.014 for PAI-1, P<0.001 for uPA).

Conclusion

In this study, the prognostic impact of uPA and PAI-1 expression was mainly observed in patients with HER2-positive tumors.

SUBMITTER: Witzel I 

PROVIDER: S-EPMC4259258 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.

Witzel Isabell I   Milde-Langosch Karin K   Schmidt Marcus M   Karn Thomas T   Becker Sven S   Wirtz Ralph R   Rody Achim A   Laakmann Elena E   Schütze Dina D   Jänicke Fritz F   Müller Volkmar V  

OncoTargets and therapy 20141128


<h4>Background</h4>Protein levels of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) determined by enzyme-linked immunosorbent assay from fresh-frozen tumor tissue have been evaluated as prognostic factors in prospectively randomized trials in breast cancer. However, the role of uPA and PAI-1 in the context of breast cancer subtypes and for mRNA expression of these factors is less clear.<h4>Methods</h4>We evaluated uPA and PAI-1 mRNA expression using the Affymetrix HG-U 133A arra  ...[more]

Similar Datasets

| S-EPMC1564186 | biostudies-literature
| S-EPMC3044959 | biostudies-literature
| S-EPMC5428408 | biostudies-literature
2011-05-03 | GSE29028 | GEO
| S-EPMC6418500 | biostudies-literature
| S-EPMC4876229 | biostudies-literature
2011-05-03 | E-GEOD-29028 | biostudies-arrayexpress
| S-EPMC3297169 | biostudies-literature
| S-EPMC6381129 | biostudies-literature
| S-EPMC3041515 | biostudies-literature